Newsletter Tool

Today’s Big News

Feb 20, 2024

Sanofi stumbles in HIMALAYA trial, chalking up phase 2 ALS fail in another blow to Denali alliance

RAPT faces 'unfortunate and unexpected' clinical hold after liver failure in atopic dermatitis trial

Everest to continue mRNA ascent alone after shedding Providence partnership

Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win

Fierce Biotech Layoff Tracker 2024: Sonata lays off 21 employees; LianBio winds down

Featured

Sanofi stumbles in HIMALAYA trial, chalking up phase 2 ALS fail in another blow to Denali alliance

By Nick Paul Taylor

Sanofi’s HIMALAYA adventure has ended in failure, dealing another blow to its RIPK1 collaboration with Denali Therapeutics.

RAPT faces 'unfortunate and unexpected' clinical hold after liver failure in atopic dermatitis trial

By Max Bayer

Rapt Therapeutics is reeling from an “unfortunate and unexpected” clinical hold after a patient in a phase 2 immunology trial experienced liver failure that may be related to the study drug.

Everest to continue mRNA ascent alone after shedding Providence partnership

By James Waldron

The collaboration between Everest Medicines and Providence Therapeutics back in 2021 marked a significant step up for the Chinese mRNA sector. Now, Everest will continue the ascent alone.

How pharma and healthcare will benefit from the adoption of ePI standards

Innovent's Tepezza rival one step closer to Chinese approval after phase 3 eye disease win

By James Waldron

Innovent Biologics is hoping that a phase 3 win for its thyroid eye disease treatment will provide a first shot at the Chinese equivalent of a market that has already been conquered by Amgen’s Tepezza in the U.S.

Fierce Biotech Layoff Tracker 2024: Sonata lays off 21 employees; LianBio winds down

By Gabrielle Masson,Max Bayer

We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs.

FDA approves Iovance's Amtagvi as first T-cell therapy for a solid tumor

By Angus Liu

The T-cell therapy treatment class, which has transformed the treatment of certain blood cancers, has now reached the solid tumor field thanks to an FDA approval for a first-of-its-kind immunotherapy developed by Iovance Biotherapeutics.

Daiichi Sankyo plots €1B expansion to beef up antibody-drug conjugate production in Germany

By Fraiser Kansteiner

Aiming to beef up development and manufacturing of antibody-drug conjugates, Daiichi Sankyo is plugging roughly €1 billion ($1.08 billion) into an expansion of its production facility in Pfaffenhofen an der Ilm, Germany.

Medtronic reverses patient monitoring spinoff plan, discontinues ventilator sales

By Andrea Park

More than a year after laying out a plan to divest its patient monitoring and respiratory interventions businesses—sparking months of speculation over potential buyers—Medtronic is reworking the reorganization.

AbbVie CEO telegraphs retirement and prepares to pass baton to long-time deputy Robert Michael

By Fraiser Kansteiner

Robert Michael, AbbVie’s current president and chief operating officer, has been tapped by the company’s board of directors to take over Richard Gonzalez’s CEO post on July 1. Gonzalez, for his part, is retiring from his role as chief executive after 11 years to become executive chairman of AbbVie’s board.

Fierce podcasts

Don’t miss an episode

'The Top Line': Gene editing's next act

This week on "The Top Line," Max Bayer from Fierce Biotech explores the future of gene editing in an interview with the CEO of Verve Therapeutics.

‘The Top Line’: The most anticipated drug launches of 2024

'Podnosis': The Fierce 15 of 2024

Resources

Whitepaper

The Oncology Market – 2023 Year in Review

This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Developing and Manufacturing Drugs with HPAPIs

Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient.